Exelixis | EXEL - 流动负债



金融业
股票价格
USD
资产
USD 2.49B
现金及等价物
USD 281.45M
销售成本
USD 20.66M
流动资产
USD 1.25B
流动负债
USD 361.93M
债务
USD 165.93M
EBIT
USD 248.41M
EBITDA
USD 255.4M
员工
1.15K
EPS每股收益
USD 0.91
股本和储备
USD 1.84B
销售毛利
USD 608.03M
债务利息支出
USD 23.4M
利息收入
USD 14.21M
市值
USD 16.89B
净收入
USD 212.05M
营业费用
USD 380.28M
营业利润
USD 248.41M
普通股股本
USD 248.89M
PE价格收益
18.02
税前利润
USD 262.68M
销售收入
USD 628.69M
销售和管理费用
USD 147.63M
股票
USD 28.73M
贸易债权人
USD 39.06M
应收帐款人
USD 322.21M


流动负债 更改 日
Acadia Pharmaceuticals USD 361.44M 55.91M 2026-06
Agios Pharmaceuticals USD 70.22M 11.37M 2026-06
Akebia Therapeutics USD 160.86M 13.02M 2026-06
Amgen USD 25.5B 547M 2026-06
AstraZeneca USD 31.55B 1.02B 2026-06
Bayer EUR 32.27B 1.19B 2026-06
BioMarin Pharmaceutical USD 1.66B 870.84M 2026-06
Bristol-Myers Squibb USD 18.66B 499M 2026-06
Cytokinetics USD 181.43M 17.76M 2026-06
Eisai JPY 393.64B 53.39B 2026-06
Eli Lilly USD 47.74B 11.11B 2026-06
Exelixis USD 361.93M 9.05M 2026-06
Genmab DKK 1.14B 38M 2026-06
Glaxosmithkline GBP 22.43B 6.39B 2026-03
Incyte USD 1.31B 177.55M 2026-06
Ionis Pharmaceuticals USD 315.64M 401.36M 2026-06
MacroGenics USD 108.82M 12.88M 2026-06
Merck USD 27.73B 786M 2026-06
Moderna USD 2.53B 139M 2026-06
Nektar Therapeutics USD 57.71M 4.17M 2026-03
Neurocrine Biosciences USD 874.5M 42.8M 2026-06
Novartis USD 31.75B 374M 2026-06
Pfizer USD 32.65B 1.7B 2026-06
Puma Biotechnology USD 82.73M 3.63M 2025-09
Sanofi EUR 30.01B 1.66B 2026-03
Takeda JPY 2.76T 335.02B 2026-06
Ultragenyx Pharmaceutical USD 351M 26M 2026-06
Xencor USD 81.86M 8.41M 2026-06